Meeting Tomorrow's Market Requirements: Vetter's Perspective on the Future of Fill & Finish

Sponsored by Vetter Pharma International GmbH

In this video, two leaders from Vetter Pharma International GmbH share their perspective on the future of fill and finish. Christine Fuerst, Director Key Account Management Europe, and Gregor Deutschle, Director Product & Service Management, explain how the CDMO is responding to evolving customer needs and market requirements. Their discussion spans the full product journey, from phase 1 and preclinical work through commercial launch and lifecycle management.

Fuerst notes that big pharma, mid-sized pharma, and biotech companies alike are looking for reliable, secure supply, compatible time to market, quality, and expertise, while startups may also need guidance on regulatory dossiers. She describes how starting early on Vetter's clinical sites supports a smoother transfer into commercial lines, and how lessons from the COVID-19 pandemic shaped Vetter's approach to supply chain resilience through diligent planning, appropriate stock levels, proactive communication, backup solutions across locations, and 10 additional lines planned over the next 5 years. Deutschle explains how Vetter is responding to increased regulatory expectations for complex biologics, patient demand for convenience, and sustainability through digital processes, renewable energy, paper-based packaging, and devices that support at-home administration. He also highlights the expansion of Vetter's US clinical site, a new commercial facility under construction in Germany, and new secondary packaging, assembly, and analytical capabilities.

Pharmaceutical and biotech professionals evaluating CDMO outsourcing partners for sterile fill and finish will gain insight into how one partner is planning capacity expansion and long-term supply security. Viewers will also come away with a clearer view of the industry trends Deutschle expects to shape fill and finish, including changing container sizes, larger injection volumes and devices, more viscous drugs, and smaller batch sizes driven by more personalized approaches.